Alcon's Simbrinza® approved in the EU to treat patients living with glaucoma
Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission to decrease elevated intraocular pressure in adult patients with open-angle glaucoma. July 28, 2014